Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.

Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D.

Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20.

2.

Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases (LAVA): study protocol for a randomised controlled trial.

Gurusamy K, Corrigan N, Croft J, Twiddy M, Morris S, Woodward N, Bandula S, Hochhauser D, Napp V, Pullan A, Jakowiw N, Prasad R, Damink SO, van Laarhoven CJHM, de Wilt JHW, Brown J, Davidson BR.

Trials. 2018 Feb 13;19(1):105. doi: 10.1186/s13063-018-2499-5.

3.

Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.

Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP, Hochhauser D, Hull MA, Koelzer VH, McNair AGK, Monahan KJ, Näthke I, Norton C, Novelli MR, Steele RJC, Thomas AL, Wilde LM, Wilson RH, Tomlinson I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative.

Gut. 2018 Jan;67(1):179-193. doi: 10.1136/gutjnl-2017-315333. Review.

4.
5.

Of mice and men: patient-derived xenografts in cancer medicine.

Hochhauser D, Caldas C.

Ann Oncol. 2017 Oct 1;28(10):2330-2331. doi: 10.1093/annonc/mdx516. No abstract available.

PMID:
28945891
6.

Autophagy and receptor tyrosine kinase signalling: A mTORC2 matter.

Lampada A, Hochhauser D, Salomoni P.

Cell Cycle. 2017 Oct 18;16(20):1855-1856. doi: 10.1080/15384101.2017.1372548. Epub 2017 Sep 21. No abstract available.

PMID:
28934018
7.

Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocation.

Tomas A, Jones S, Vaughan SO, Hochhauser D, Futter CE.

J Cell Sci. 2017 Aug 1;130(15):2481-2490. doi: 10.1242/jcs.202358. Epub 2017 Jun 23.

8.

Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision.

Singer R, Campbell P, Fernandes C, Statham P, Hochhauser D, Bridgewater J.

BMC Cancer. 2017 May 25;17(1):365. doi: 10.1186/s12885-017-3335-0.

9.

mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism.

Lampada A, O'Prey J, Szabadkai G, Ryan KM, Hochhauser D, Salomoni P.

Cell Death Differ. 2017 Jun;24(6):1045-1062. doi: 10.1038/cdd.2017.41. Epub 2017 May 5.

10.

Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.

Pett L, Kiakos K, Satam V, Patil P, Laughlin-Toth S, Gregory M, Bowerman M, Olson K, Savagian M, Lee M, Lee M, Wilson WD, Hochhauser D, Hartley JA.

Biochim Biophys Acta. 2017 May;1860(5):617-629. doi: 10.1016/j.bbagrm.2016.10.005. Epub 2016 Oct 24.

11.

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.

Vena F, Hartley JA, Hochhauser D.

Clin Cancer Res. 2016 May 15;22(10):2595. doi: 10.1158/1078-0432.CCR-16-0566. No abstract available. Erratum in: Clin Cancer Res. 2016 Nov 15;22(22):5619.

12.

Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal Liver Metastases (CRLM): Looking Beyond the Tumor Margin.

Siriwardana PN, Luong TV, Watkins J, Turley H, Ghazaley M, Gatter K, Harris AL, Hochhauser D, Davidson BR.

Medicine (Baltimore). 2016 Feb;95(8):e2924. doi: 10.1097/MD.0000000000002924.

13.

Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.

Chung R, Maulik A, Hamarneh A, Hochhauser D, Hausenloy DJ, Walker JM, Yellon DM.

Clin Cardiol. 2016 Feb;39(2):72-82. doi: 10.1002/clc.22507. Epub 2016 Jan 25.

14.

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.

Santoro V, Jia R, Thompson H, Nijhuis A, Jeffery R, Kiakos K, Silver AR, Hartley JA, Hochhauser D.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv394. doi: 10.1093/jnci/djv394. Print 2016 Jun.

15.

NF-Y activates genes of metabolic pathways altered in cancer cells.

Benatti P, Chiaramonte ML, Lorenzo M, Hartley JA, Hochhauser D, Gnesutta N, Mantovani R, Imbriano C, Dolfini D.

Oncotarget. 2016 Jan 12;7(2):1633-50. doi: 10.18632/oncotarget.6453.

16.

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.

De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H.

Br J Cancer. 2015 Nov 3;113(9):1305-12. doi: 10.1038/bjc.2015.342. Epub 2015 Oct 20.

17.

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).

Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D.

Clin Cancer Res. 2015 Dec 15;21(24):5563-77. doi: 10.1158/1078-0432.CCR-15-0485. Epub 2015 Jul 30.

18.

Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence-Selective p-Anisyl-benzimidazolecarboxamido Imidazole-Pyrrole Polyamide.

Kiakos K, Pett L, Satam V, Patil P, Hochhauser D, Lee M, Hartley JA.

Chem Biol. 2015 Jul 23;22(7):862-75. doi: 10.1016/j.chembiol.2015.06.005. Epub 2015 Jun 25.

19.

WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway.

Tomas A, Vaughan SO, Burgoyne T, Sorkin A, Hartley JA, Hochhauser D, Futter CE.

Nat Commun. 2015 Jun 12;6:7324. doi: 10.1038/ncomms8324.

20.

Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer.

Vassileva V, Rajkumar V, Mazzantini M, Robson M, Badar A, Sharma S, Årstad E, Hochhauser D, Lythgoe MF, Kinghorn J, Boxer GM, Pedley RB.

J Nucl Med. 2015 Aug;56(8):1239-45. doi: 10.2967/jnumed.115.157362. Epub 2015 Jun 4. Erratum in: J Nucl Med. 2015 Nov;56(11):1807. Kinghorn, Jane [added].

21.

Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.

Murugaesu N, Wilson GA, Birkbak NJ, Watkins T, McGranahan N, Kumar S, Abbassi-Ghadi N, Salm M, Mitter R, Horswell S, Rowan A, Phillimore B, Biggs J, Begum S, Matthews N, Hochhauser D, Hanna GB, Swanton C.

Cancer Discov. 2015 Aug;5(8):821-831. doi: 10.1158/2159-8290.CD-15-0412. Epub 2015 May 23.

22.

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.

Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA.

Oncotarget. 2015 Apr 30;6(12):10548-62.

23.

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR.

Cancer Res. 2015 Apr 1;75(7):1255-64. doi: 10.1158/0008-5472.CAN-14-1801. Epub 2015 Feb 10.

24.

Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage.

Liccardi G, Hartley JA, Hochhauser D.

Clin Cancer Res. 2014 Jul 1;20(13):3496-506. doi: 10.1158/1078-0432.CCR-13-2695. Epub 2014 Apr 29.

25.

The diagnosis and management of gastric cancer.

Thrumurthy SG, Chaudry MA, Hochhauser D, Mughal M.

BMJ. 2013 Nov 4;347:f6367. doi: 10.1136/bmj.f6367. Review. No abstract available.

PMID:
24191271
26.

Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.

Bhosle J, Kiakos K, Porter AC, Wu J, Makris A, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2013 Dec;12(12):2897-908. doi: 10.1158/1535-7163.MCT-12-1049. Epub 2013 Oct 3.

27.

An extended pyrrolobenzodiazepine-polyamide conjugate with selectivity for a DNA sequence containing the ICB2 transcription factor binding site.

Brucoli F, Hawkins RM, James CH, Jackson PJ, Wells G, Jenkins TC, Ellis T, Kotecha M, Hochhauser D, Hartley JA, Howard PW, Thurston DE.

J Med Chem. 2013 Aug 22;56(16):6339-51. doi: 10.1021/jm4001852. Epub 2013 Jul 26.

PMID:
23889553
28.

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.

Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK.

Br J Cancer. 2013 Apr 2;108(6):1252-9. doi: 10.1038/bjc.2013.85. Epub 2013 Feb 28.

29.

A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA.

Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.

30.

γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).

Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA.

Clin Cancer Res. 2013 Feb 1;19(3):721-30. doi: 10.1158/1078-0432.CCR-12-2529. Epub 2012 Dec 18.

31.

Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K, Craddock C, Ledermann JA, Hochhauser D, Hartley JA.

BMC Cancer. 2012 Sep 28;12:436. doi: 10.1186/1471-2407-12-436.

32.

Small molecule drugs - optimizing DNA damaging agent-based therapeutics.

Hartley JA, Hochhauser D.

Curr Opin Pharmacol. 2012 Aug;12(4):398-402. doi: 10.1016/j.coph.2012.03.008. Epub 2012 Apr 11. Review.

PMID:
22503290
33.

EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Liccardi G, Hartley JA, Hochhauser D.

Cancer Res. 2011 Feb 1;71(3):1103-14. doi: 10.1158/0008-5472.CAN-10-2384. Epub 2011 Jan 25.

34.

Targeting the ICB2 site of the topoisomerase IIalpha promoter with a formamido-pyrrole-imidazole-pyrrole H-pin polyamide.

Franks A, Tronrud C, Kiakos K, Kluza J, Munde M, Brown T, Mackay H, Wilson WD, Hochhauser D, Hartley JA, Lee M.

Bioorg Med Chem. 2010 Aug 1;18(15):5553-61. doi: 10.1016/j.bmc.2010.06.041. Epub 2010 Jun 17.

PMID:
20615712
35.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T.

Br J Cancer. 2010 Mar 30;102(7):1106-12. doi: 10.1038/sj.bjc.6605618. Epub 2010 Mar 16.

36.

Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents.

Boone JJ, Bhosle J, Tilby MJ, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2009 Nov;8(11):3015-23. doi: 10.1158/1535-7163.MCT-09-0219. Epub 2009 Nov 3.

37.

Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.

Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, Cobb M, Gumbrell L, Begent RH, Hartley JA, Jodrell D.

Clin Cancer Res. 2009 Mar 15;15(6):2140-7. doi: 10.1158/1078-0432.CCR-08-1315. Epub 2009 Mar 10.

38.

Primary tumour resection and survival in the palliative management of metastatic colorectal cancer.

Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, Ledermann JA, O'Bichere A.

Eur J Surg Oncol. 2009 Feb;35(2):164-7. doi: 10.1016/j.ejso.2008.06.005. Epub 2008 Jul 21.

PMID:
18644695
39.

Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients.

Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, Witney-Smith C, Amin T, Bhogal P, Sivathasan N, Warner B, Hochhauser D, Caplin ME.

Br J Cancer. 2008 Jul 8;99(1):72-7. doi: 10.1038/sj.bjc.6604428. Epub 2008 Jun 24.

40.

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78.

Kotecha M, Kluza J, Wells G, O'Hare CC, Forni C, Mantovani R, Howard PW, Morris P, Thurston DE, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2008 May;7(5):1319-28. doi: 10.1158/1535-7163.MCT-07-0475.

41.

The role of 99mTc-depreotide in the management of neuroendocrine tumours.

Shah T, Kulakiene I, Quigley AM, Warbey VS, Srirajaskanthan R, Toumpanakis C, Hochhauser D, Buscombe J, Caplin ME.

Nucl Med Commun. 2008 May;29(5):436-40. doi: 10.1097/MNM.0b013e3282f50747.

PMID:
18391727
42.

Targeting the inverted CCAAT Box-2 of the topoisomerase IIalpha gene: DNA sequence selective recognition by a polyamide-intercalator as a staggered dimer.

Mackay H, Brown T, Sexton JS, Kotecha M, Nguyen B, Wilson WD, Kluza J, Savic B, O'Hare C, Hochhauser D, Lee M, Hartley JA.

Bioorg Med Chem. 2008 Feb 15;16(4):2093-102. Epub 2007 Oct 22.

PMID:
17977733
43.

A comparison of Hickman line- and Port-a-Cath-associated complications in patients with solid tumours undergoing chemotherapy.

Ng F, Mastoroudes H, Paul E, Davies N, Tibballs J, Hochhauser D, Mayer A, Begent R, Meyer T.

Clin Oncol (R Coll Radiol). 2007 Sep;19(7):551-6. Epub 2007 May 22.

PMID:
17517500
44.

Well-differentiated gastric tumors/carcinomas.

Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G; Frascati Consensus Conference; European neuroendocrine Tumor Society.

Neuroendocrinology. 2006;84(3):158-64. Epub 2007 Feb 20. No abstract available.

PMID:
17312375
45.

Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.

Hochhauser D, Kotecha M, O'hare C, Morris PJ, Hartley JM, Taherbhai Z, Harris D, Forni C, Mantovani R, Lee M, Hartley JA.

Mol Cancer Ther. 2007 Jan;6(1):346-54.

46.

Binding of f-PIP, a pyrrole- and imidazole-containing triamide, to the inverted CCAAT box-2 of the topoisomerase IIalpha promoter and modulation of gene expression in cells.

Le NM, Sielaff AM, Cooper AJ, Mackay H, Brown T, Kotecha M, O'Hare C, Hochhauser D, Lee M, Hartley JA.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6161-4. Epub 2006 Sep 29.

PMID:
17011187
47.

Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase IIalpha promoter.

Flores LV, Staples AM, Mackay H, Howard CM, Uthe PB, Sexton JS 3rd, Buchmueller KL, Wilson WD, O'Hare C, Kluza J, Hochhauser D, Hartley JA, Lee M.

Chembiochem. 2006 Nov;7(11):1722-9.

PMID:
16991167
48.

Epidermal growth factor receptor expression and activation in neuroendocrine tumours.

Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME.

J Neuroendocrinol. 2006 May;18(5):355-60.

PMID:
16629834
49.

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.

Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D.

Mol Cancer Ther. 2006 Feb;5(2):209-18.

50.

Design of a hairpin polyamide, ZT65B, for targeting the inverted CCAAT box (ICB) site in the multidrug resistant (MDR1) gene.

Buchmueller KL, Taherbhai Z, Howard CM, Bailey SL, Nguyen B, O'Hare C, Hochhauser D, Hartley JA, Wilson WD, Lee M.

Chembiochem. 2005 Dec;6(12):2305-11.

PMID:
16254941

Supplemental Content

Loading ...
Support Center